Skip to main content
SpringerLink
Log in

Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia

Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 – November 1, 1989

  • Conference proceedings
  • © 1990

Overview

Editors:
  1. Joel Morganroth

    1. Likoff Cardiovascular Institute of Hahnemann Medical College and Hospital, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. E. Neil Moore

    1. School of Veterinary Medicine, University of Pennsylvania, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Developments in Cardiovascular Medicine (DICM, volume 112)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (14 papers)

  1. Front Matter

    Pages i-x
    Download chapter PDF

  2. Approaches and Methods to Studying Antihypertensive Drugs

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. New Concepts in Antihypertensive Drug Therapy

      • William H. Frishman
      Pages 3-12

    3. Is Ambulatory Blood Pressure Monitoring Required to Define the Hypertensive Patient and to Detect Efficacy?

      • William B. White
      Pages 13-24

    4. What Vascular Effects Should be Measured in Antihypertensive Drug Research?

      • Jay N. Cohn
      Pages 25-34

    5. Is It Necessary to Demonstrate Changes in Left Ventricular Hypertrophy in the Evaluation of Antihypertensive Drugs?

      • Thomas G. Pickering, Richard B. Devereux
      Pages 35-43

    6. Clinical Trials of Antihypertensive Agents

      • M. A. Weber, J. M. Neutel, D. H. G. Smith
      Pages 45-65

    7. How Does One Define Dose-Duration of an Antihypertensive Drug? What is the Role of Non-Mem and the Peak/Through Measurement?

      • Raymond J. Lipicky
      Pages 67-89

  5. Back Matter

    Pages 224-230
    Download chapter PDF
Back to top

Keywords

About this book

The Symposium on New Drugs provides for an annual forum for academic investigators, research and development personnel from the pharmaceutical and related health care industries, and members of the Food and Drug Administration to discuss important clinical research issues. The Tenth Annual Symposium on New Drugs addressed the problem of whether it was still appropriate to approve antihypertensive agents soley on the endpoint of lowering cuff blood pressure. The initial discussions at this symposium related to the approaches and methods to studying antihypertensive agents. Dr. William Frishman provided a detailed list of the new approaches to the treatment of hypertension and pointed out the many new concepts that are currently active in the development of many new antihypertensive agents. Dr. William White detailed the growing importance of ambulatory blood pressure monitoring to define hypertension and to determine the change in blood pressure due to pharmacologically active agents. Dr. Jay Cohn pointed out the flaws in using cuff blood pressure and detailed the potential virtues of using vascular compliance to identify patients requiring treatment for hypertension. Dr. Thomas Pickering also discussed the potential value of evaluating changes in left ventricular hypertrophy a finding which identifies high risk patients who need to be included in clinical trials. Dr. Michael Weber detailed the issues and suggested refinements in the approaches to clinical trial designs for antihypertensive agents and Dr. Raymond Lipicky discussed the definition of dose-duration and the role of non-Mem and Peak/Through measurements in defining an antihypertensive drug effect.

Editors and Affiliations

  • Likoff Cardiovascular Institute of Hahnemann Medical College and Hospital, USA

    Joel Morganroth

  • School of Veterinary Medicine, University of Pennsylvania, USA

    E. Neil Moore

Bibliographic Information

  • Book Title: Use and Approval of Antihypertensive Agents and Surrogate Endpoints for the Approval of Drugs Affecting Antiarrhythmic Heart Failure and Hypolipidemia

  • Book Subtitle: Proceedings of the Tenth Annual Symposium on New Drugs & Devices, October 31 – November 1, 1989

  • Editors: Joel Morganroth, E. Neil Moore

  • Series Title: Developments in Cardiovascular Medicine

  • DOI: https://doi.org/10.1007/978-1-4613-1505-6

  • Publisher: Springer New York, NY

  • eBook Packages: Springer Book Archive

  • Copyright Information: Kluwer Academic Publishers 1990

  • Hardcover ISBN: 978-0-7923-0756-3Published: 31 May 1990

  • Softcover ISBN: 978-1-4612-8809-1Published: 05 October 2011

  • eBook ISBN: 978-1-4613-1505-6Published: 06 December 2012

  • Series ISSN: 0166-9842

  • Edition Number: 1

  • Number of Pages: X, 230

  • Topics: Cardiology

Publish with us

Policies and ethics

Back to top

Search

Navigation